HC Wainwright Sees Agile Therapeutics' Twirla Tailwinds Post Roe-Wade Ruling
Agile Therapeutics Inc's (NASDAQ: AGRX) Twirla, the only low-dose transdermal hormonal contraceptive, should have tailwinds protected after the Supreme Court overturned Roe vs. Wade ruling that legalized abortion nationwide.
H.C. Wainwright expects prescription acceleration soon with non-retail channel ramping and Washington forcing coverage with the Affordable Care Act provisions assuring women straightforward, no-cost access to contraceptives.
The analyst has raised the price target to $5 from $2.50 and reiterated a Buy.
Related: Agile Therapeutics Tightens Q2 Forecast For Contraceptive Patch 'Twirla.'
Management indicates that Afaxys with meaningful institutional orders were likely also stirred by Roe. Large accounts, having switched to Twirla from high-dose Xulane, are still working down the remaining Xulane inventory.
The analyst thinks that if Twirla accelerates along with a lower cost-base, exiting this year, 2024 could potentially break even and re-rate the shares.
Also, additional consolidation in the revenue-generating women's health space, thus potential Agile strategic optionality.
Price Action: AGRX shares are down 3.70% at $0.66 during the market session on the last check Tuesday.
Latest Ratings for AGRX
Date | Firm | Action | From | To |
|---|---|---|---|---|
Nov 2021 | HC Wainwright & Co. | Maintains | Buy | |
Sep 2021 | HC Wainwright & Co. | Maintains | Buy | |
Jul 2021 | RBC Capital | Maintains | Outperform |
View More Analyst Ratings for AGRX
View the Latest Analyst Ratings
See more from Benzinga
Agile Therapeutics Tightens Q2 Forecast For Contraceptive Patch 'Twirla'
President Biden Mulls Health Emergency For Abortion Access: Report
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
